製品の状態Lyophilised:Reconstitute with 200µl of sterile water. Please note that if you receive this product in liquid form it has already been reconstituted as described and no further reconstitution is necessary.
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term.
バッファーPBS, pH 7.4, no preservative, sterile filtered
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 0.1 - 0.2 µg/ml.
To detect hIL-7 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hIL-7 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Use a concentration of 0.04 - 0.06 µg/ml.
To yield one-half maximal inhibition [ND50] of the biological activity of hIL-7 (1.0 ng/ml), a concentration of 0.04 – 0.06 µg/ml of this antibody is required.
To detect Human IL-7 by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with ab84254 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human IL-7.
機能Hematopoietic growth factor capable of stimulating the proliferation of lymphoid progenitors. It is important for proliferation during certain stages of B-cell maturation.
All lanes : Anti-IL7 antibody (ab9628) at 0.2 µg/ml
Lane 1 : Recombinant human IL7 protein (ab73201) at 0.1 µg Lane 2 : Recombinant human IL7 protein (ab73201) at 0.01 µg
Secondary Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution Developed using the ECL technique
Performed under reducing conditions.
Exposure time : 10 seconds
Anti-IL7 antibody (ab9628) 使用論文
This product has been referenced in:
Cai YJ et al. Up-regulation of intestinal epithelial cell derived IL-7 expression by keratinocyte growth factor through STAT1/IRF-1, IRF-2 pathway. PLoS One8:e58647 (2013).
Read more (PubMed: 23554911) »